Big pharma has faced many evolutions to the pharma playbook of old. New technologies such as wearables introduce behavioral change to patients, while e-commerce giants such as Amazon seek a piece of the Rx action. The health care industry has done a reasonable job of weathering the storm inflicted on its core business model over the years, but it has yet to be a true disruptor. As the world marches on is pharma’s choice to disrupt, or inevitably be disrupted for good?

In this latest edition of the Lab Links series on notable figures responsible for major advances in drug discovery, In Vivo talks to Harvard Medical School professor and biologist Timothy Springer on his 50-year record as an academic scientist, business entrepreneur and philanthropist. His latest venture is being co-founder – and principal funder – of the independent non-profit Institute for Protein Innovation, an institution designed to fill a critical niche in open-source biomedical research.

The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.

Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.